When the Ingredient Is the Drug Claim

what does 101.93(g)(2)(iv)(B) say a disease claim can be built from?

21 CFR 101.93(g)(2)(iv)(B) builds a disease claim out of an ingredient's identity alone, with no separate efficacy sentence required anywhere on the page. The current eCFR text reaches any labeling that describes an ingredient "regulated by FDA as a drug and is well known to consumers for its use or claimed use in preventing or treating a disease." The trigger sits in the ingredient's reputation, not in whatever the label goes on to promise about results.

It's one of five ways paragraph (iv) alone can create a disease claim — alongside the product's name, its formulation, a cited publication, and imagery — inside a longer list of ten triggers under (g)(2) overall. Naming the disease is optional throughout; FDA built the whole structure to catch what labeling implies, not only what it states outright.

why is monacolin k the reason red yeast rice is discussed at all?

Monacolin K is the reason red yeast rice gets discussed under this clause at all: it's the compound the rice produces during fermentation, and it is chemically identical to lovastatin, a statin FDA approved as a prescription drug decades before any supplement brand touched red yeast rice. That identity is exactly what (iv)(B) is built to reach — an ingredient regulated by FDA as a drug, sitting inside a product sold as a dietary supplement rather than a drug, where the chemistry is well known even if the ingredient name on the label isn't.

We counted the hits before writing this: a full-text search of FDA's warning letter database for "red yeast rice" turns up only 4 letters, against 105 for "cholesterol" generally and 146 for "diabetes" — counts spanning every FDA-regulated product type, not supplements alone, so read them as a rough proxy for attention rather than a supplement-specific tally.

Low volume here doesn't mean low risk.

has fda published a statement applying that criterion to red yeast rice by name?

No — we could not find one, and we're saying so directly rather than picking the convenient answer. FDA's warning letter database returns exactly 4 letters mentioning red yeast rice, and none we located cites 101.93(g)(2)(iv)(B) by number against red yeast rice's tie to a prescription statin.

What would settle it is a direct read of those 4 letters in full, or a future FDA letter that quotes the subparagraph by number the way other letters in this record quote adjacent ones.

The closer parallel on file is (iv)(A), the product-name trigger, a different subparagraph in the same list. FDA cited BergaMet North America's own product name, "Cholesterol Command," as independently actionable evidence in its Nov. 14, 2022 letter, which shows the agency does invoke the specific-subparagraph structure of (iv) in practice — just not yet, on the public record we searched, against red yeast rice.

does attributing a claim to an ingredient instead of the product break the chain?

No — FDA has already answered this, and the record runs against the intuition that ingredient-level phrasing is safer. In the Essential Elements warning letter (MARCS-CMS 636305, Nov. 14, 2022), FDA treated statements about what an ingredient does as evidence against the finished product.

FDA cited the company's language about LDL — the marker doctors call bad cholesterol — reading that "red yeast rice … has been shown to lower LDL cholesterol by helping inhibit cholesterol production in the liver." A companion line about "garlic powder" made the same move: describing what a component does to cholesterol reads to FDA as a claim about what the bottle as a whole does, and the ingredient tab is exactly where FDA went looking, which is why the ingredient tab is where the claim gets made as a rule, not an exception.

The hedge didn't survive either. FDA quoted the company's blunt "Helps Reduce LDL Levels" alongside its Amazon copy reading "[A]id your body in potentially lowering bad cholesterol levels," and cited both as equally probative of drug intent. Softening the verb doesn't move a sentence out of (g)(2); it adds a second sentence FDA can quote.

serious-disease flag: how does the hypercholesterolemia classification raise the stakes?

Cholesterol isn't a risk factor in FDA's framing — it's the disease itself, and that reclassification is what raises the ceiling on every claim downstream of it. In its 2000 final rule, FDA wrote that "elevated blood pressure (hypertension) and elevated cholesterol (hypercholesterolemia) are diseases themselves, with subsequent events (heart attack, stroke) the late consequences of those diseases." Addressing the number is addressing the disease, not managing a precursor to one.

The permitted sentence is narrow, and FDA rejected the obvious alternative wording advertisers reach for first. It approved only "helps to maintain cholesterol levels that are already within the normal range," and rejected "maintains healthy cholesterol" because that phrase is now commonly read as referring to HDL instead. "Lowers cholesterol, however qualified," stays an implied disease claim regardless of hedge — the same standard the cholesterol niche's claim ceiling runs on across the whole vertical, not just this one ingredient.

how should a media buyer read an ingredient panel before taking an offer?

Read the ingredient panel the way FDA's investigators do: as evidence of intended use, not as a footnote sitting under the headline claim. FDA's letter to BergaMet North America quoted the express claim that "BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL," and treated that sentence — on a product literally named "Cholesterol Command" — as most of the case by itself.

Before you run an offer built on red yeast rice, check four things on the panel and the landing page together, because FDA reads them as one exhibit: whether the headline or the ingredient description uses a disease name or a lab marker like LDL as its subject rather than a maintenance phrase; whether a guarantee promises a specific number or outcome instead of a refund on dissatisfaction; whether the brand's own social accounts reply to or like testimonials that mention stopping a prescription; and whether any sentence attributes an effect to the ingredient that the product page itself avoids saying directly. A single yes on any of those four is enough exposure to walk, because FDA's own enforcement record treats each one as independently sufficient, not cumulative.

The same mistake shows up wherever a claim hides one layer down from the headline instead of in it — a sleep offer stacked with anxiety claims runs the identical exposure through a bundle rather than an ingredient tab.

which parts of this are settled regulation and which are still open?

Settled: the regulation's text, the cholesterol-as-disease classification, the permitted and forbidden phrasing, and the enforcement pattern FDA used against BergaMet and Essential Elements in its Nov. 14, 2022 sweep of five same-day letters. None of that depends on red yeast rice specifically — it's the general disease-claim machinery this ingredient happens to sit inside, whichever ingredient a given offer runs.

Open: whether FDA has ever pointed (iv)(B) at red yeast rice by name, rather than folding its claims into the general disease-claim provisions the way Essential Elements was charged. We flagged that gap instead of filling it with a guess.

That's the honest state of the record.

The same split between codified rule and observed enforcement pattern runs through this desk's other claim-ceiling breakdowns, including the prostate niche's buyer and claim economics, where a different ingredient carries a comparable identity risk.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Candida and Yeast Offers: A Market Built on an Unofficial Diagnosis, Overweight vs Obesity: The Line FDA Drew for Ads, The 7 Weight Loss Claims the FTC Calls Always False, Your Study Included Diet and Exercise. Say So., and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.